New drug watch: mogamulizumab under Real-World scrutiny for rare skin cancers

NCT ID NCT07132567

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This study tracks 15 adults with mycosis fungoides or Sezary syndrome who receive mogamulizumab, a targeted antibody therapy, in everyday medical practice. Researchers will record side effects and measure how well the drug controls the cancer using a standard scoring system. The goal is to confirm the drug's safety and effectiveness outside of controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chung-Ang University Hospital

    TERMINATED

    Seoul, South Korea

  • Ewha Womans University Mokdong Hospital

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Kosin University Gospel Hospital

    RECRUITING

    Busan, Busan Metropolitan City, 49267, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.